Core Insights - Abbott reported revenue of $11.14 billion for the quarter ended June 2025, reflecting a 7.4% increase year-over-year and a surprise of +0.63% over the Zacks Consensus Estimate of $11.07 billion [1] - The earnings per share (EPS) was $1.26, up from $1.14 in the same quarter last year, with an EPS surprise of +0.8% compared to the consensus estimate of $1.25 [1] Financial Performance Metrics - Net sales in Diagnostics (U.S.) were $811 million, slightly below the average estimate of $832.19 million, showing a year-over-year change of -0.1% [4] - International Nutrition net sales were $1.26 billion, matching the average estimate and reflecting a year-over-year increase of +3.1% [4] - U.S. Nutrition net sales reached $957 million, below the average estimate of $985.2 million, with a year-over-year increase of +2.6% [4] - International Diagnostics net sales were $1.36 billion, slightly below the average estimate of $1.38 billion, showing a year-over-year decline of -1.5% [4] - Established Pharmaceuticals net sales were $1.38 billion, exceeding the average estimate of $1.37 billion, with a year-over-year increase of +6.9% [4] - Total Diagnostics net sales were $2.17 billion, below the average estimate of $2.22 billion, reflecting a year-over-year change of -1% [4] - Medical Devices in Diabetes Care reported net sales of $1.98 billion, surpassing the average estimate of $1.94 billion, with a significant year-over-year increase of +20.2% [4] - Total Nutrition net sales were $2.21 billion, slightly below the average estimate of $2.24 billion, with a year-over-year increase of +2.9% [4] - Medical Devices in Structural Heart reported net sales of $636 million, below the average estimate of $643.65 million, with a year-over-year increase of +12.8% [4] - Heart Failure Medical Devices net sales were $368 million, exceeding the average estimate of $350.99 million, reflecting a year-over-year increase of +14.6% [4] - Electrophysiology Medical Devices net sales reached $700 million, surpassing the average estimate of $671.21 million, with a year-over-year increase of +11.6% [4] - Vascular Medical Devices net sales were $757 million, slightly above the average estimate of $754.03 million, with a year-over-year increase of +4.6% [4] Stock Performance - Abbott's shares have returned -0.5% over the past month, while the Zacks S&P 500 composite has increased by +4.2% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - Archer Daniels Midland (ADM) reported a revenue of $20.18 billion for the quarter ended March 2025, which is a decrease of 7.7% compared to the same period last year [1] - The earnings per share (EPS) for the quarter was $0.70, down from $1.46 in the year-ago quarter, with a surprise of +1.45% against the consensus estimate of $0.69 [1] Financial Performance - The reported revenue fell short of the Zacks Consensus Estimate of $20.69 billion, resulting in a surprise of -2.51% [1] - ADM's stock has returned +10.5% over the past month, compared to the Zacks S&P 500 composite's +11.5% change, indicating a performance in line with the broader market [3] Segment Performance - Processed volumes for Oilseeds were reported at 9,091 Kmt, slightly below the average estimate of 9,152.33 Kmt [4] - Revenue from Carbohydrate Solutions was $2.57 billion, compared to the estimated $2.70 billion, reflecting a -4.2% change year-over-year [4] - Revenue from Ag Services and Oilseeds was $15.68 billion, below the average estimate of $16.07 billion, representing a -9% year-over-year change [4] - Nutrition segment revenue was $1.82 billion, slightly below the estimated $1.85 billion, with a -1% change compared to the previous year [4] - Adjusted segment operating profit for Carbohydrate Solutions was $240 million, exceeding the average estimate of $224.98 million [4] - Adjusted segment operating profit for Nutrition was $95 million, significantly higher than the average estimate of $43.30 million [4] - Adjusted segment operating profit for Ag Services and Oilseeds was $412 million, below the average estimate of $454.27 million [4]